Pre-made Ranibizumab benchmark antibody ( Fab, anti-VEGFA therapeutic antibody, Anti-VPF/VEGF/MVCD1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Ranibizumab biosimilar, Fab, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ranibizumab (trade name Lucentis among others) is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-470-1mg	1mg	3090
GMP-Bios-ab-470-10mg	10mg	Inquiry
GMP-Bios-ab-470-100mg	100mg	Inquiry
GMP-Bios-ab-470-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Ranibizumab biosimilar, Fab, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibody
INN Name	Ranibizumab
Target	VEGFA
Format	Fab
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	1cz8:HL:YX
99% SI Structure	None
95-98% SI Structure	1bj1:HL:KJ/6bft:HL:AB
Year Proposed	2004
Year Recommended	2004
Companies	Genentech;Manhattan Eye Ear & Throat Hospital;Novartis Ophthalmics;University of Bonn
Conditions Approved	Choroidal neovascularisation;Degenerative myopia;Diabetic macular oedema;Retinal oedema;Wet age-related macular degeneration;Diabetic retinopathy
Conditions Active	Retinopathy of prematurity;Polypoidal choroidal vasculopathy
Conditions Discontinued	Retinal telangiectasis
Development Tech	na